Additional Data in Expanded Patient Populations and New Indications Support the Practice of Biosimilar-to-Biosimilar Switching
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Additional Data in Expanded Patient Populations and New Indications Support the Practice of Biosimilar-to-Biosimilar Switching ; volume:38 ; number:3 ; day:23 ; month:3 ; year:2024 ; pages:331-339 ; date:5.2024
BioDrugs ; 38, Heft 3 (23.3.2024), 331-339, 5.2024
- Creator
-
Cohen, Hillel P.
Bodenmueller, Wolfram
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40259-024-00655-4
- URN
-
urn:nbn:de:101:1-2407111545570.722572464412
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:57 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Cohen, Hillel P.
- Bodenmueller, Wolfram
- SpringerLink (Online service)
Other Objects (12)
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies
AVT02: An Adalimumab Biosimilar
SB8: A Bevacizumab Biosimilar
AVT04: An Ustekinumab Biosimilar
MYL-1402O: A Bevacizumab Biosimilar
Mitigating the Nocebo Effect in Biosimilar Use and Switching: A Systematic Review
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab
PF-06438179/GP1111: An Infliximab Biosimilar
Correction to: AVT04: An Ustekinumab Biosimilar
Statistical topics in clinical biosimilar development
Correction to: SB8: A Bevacizumab Biosimilar
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies
AVT02: An Adalimumab Biosimilar
SB8: A Bevacizumab Biosimilar
AVT04: An Ustekinumab Biosimilar
MYL-1402O: A Bevacizumab Biosimilar
Mitigating the Nocebo Effect in Biosimilar Use and Switching: A Systematic Review
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab
PF-06438179/GP1111: An Infliximab Biosimilar
Correction to: AVT04: An Ustekinumab Biosimilar
Statistical topics in clinical biosimilar development
Correction to: SB8: A Bevacizumab Biosimilar
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies
AVT02: An Adalimumab Biosimilar
SB8: A Bevacizumab Biosimilar
AVT04: An Ustekinumab Biosimilar
MYL-1402O: A Bevacizumab Biosimilar
Mitigating the Nocebo Effect in Biosimilar Use and Switching: A Systematic Review
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab
PF-06438179/GP1111: An Infliximab Biosimilar
Correction to: AVT04: An Ustekinumab Biosimilar
Statistical topics in clinical biosimilar development